PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-90.13%
Revenue decline while AXSM shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-148.93%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
-595.65%
Margin decline while AXSM shows 0.00% expansion. Joel Greenblatt would examine competitive position.
15.04%
R&D growth above 1.5x AXSM's 4.56%. Michael Burry would check for spending discipline.
33.15%
G&A growth while AXSM reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.43%
Operating expenses growth while AXSM reduces costs. John Neff would investigate differences.
20.43%
Total costs growth while AXSM reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
3.01%
D&A growth 1.1-1.25x AXSM's 2.56%. Bill Ackman would demand investment justification.
-24.86%
EBITDA decline while AXSM shows 2.44% growth. Joel Greenblatt would examine position.
-1164.87%
EBITDA margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-24.41%
Operating income decline while AXSM shows 2.39% growth. Joel Greenblatt would examine position.
-1160.31%
Operating margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-17.39%
Other expenses reduction while AXSM shows 7.28% growth. Joel Greenblatt would examine advantage.
-24.71%
Pre-tax income decline while AXSM shows 2.60% growth. Joel Greenblatt would examine position.
-1163.35%
Pre-tax margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-24.71%
Net income decline while AXSM shows 2.60% growth. Joel Greenblatt would examine position.
-1163.35%
Net margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-23.33%
EPS decline while AXSM shows 3.23% growth. Joel Greenblatt would examine position.
-23.33%
Diluted EPS decline while AXSM shows 3.23% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.